Composition for culturing liver organoids and method for producing liver organoids using same
A culture composition using R-spondin 3, Neuregulin-1, basic fibroblast growth factor, IGF-1, and CHIR99021 addresses the limitations of existing liver models by producing liver organoids with improved genetic identity and functionality, enhancing drug screening accuracy and reducing costs.
Patent Information
- Application Number
- PCT/KR2024/006259
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-14
AI Technical Summary
Current in vitro and in vivo liver models have limitations in reflecting human liver physiology, particularly in drug toxicity prediction and drug metabolism, due to differences between species, and primary human hepatocytes are limited by accessibility and unstable function, necessitating a more effective liver model that can simulate human liver metabolism and drug metabolism.
A culture composition containing R-spondin 3 conditioned medium, Neuregulin-1, basic fibroblast growth factor, IGF-1, and CHIR99021 is used to produce liver organoids with improved genetic identity and functionality, allowing for the formation of both normal and liver cancer organoids with enhanced cell survival and toxicity sensitivity, reducing the need for separate initial and expansion culture media.
The composition enables the production of liver organoids with higher expression levels of liver markers, improved genetic identity with patient tissue, and increased accuracy in drug screening, while reducing manufacturing costs and time, and enhancing the efficiency of liver cancer organoid formation.
Smart Images

Figure KR2024006259_14112024_PF_FP_ABST
Abstract
Description
Liver organoid culture composition and method for producing liver organoids using the same
[0001] The present invention relates to a liver organoid culture composition, and more specifically, to a composition comprising NRG1, GHIR99021, etc. as active ingredients, which can be used as a culture medium, and which can increase the genetic identity with the original tissue and improve the cell growth rate.
[0002] The liver is a central organ of metabolic and physiological homeostasis, with diverse functions such as metabolism, protein synthesis, bile production, and red blood cell removal. Hepatocytes, parenchymal liver cells, are primarily responsible for maintaining liver homeostasis and are therefore targets of numerous diseases. Despite recent technological advances in disease modeling of liver failure, models of congenital and progressive metabolic diseases that can lead to end-stage liver failure remain necessary. Furthermore, because the liver possesses a unique function in drug detoxification, models that mimic human hepatocytes are essential for drug metabolism and toxicity assessment in drug development. Current in vitro and in vivo liver models have significantly contributed to elucidating the pathogenesis of liver disease and assessing drug safety, but they still fail to fully reflect human liver physiology. Animal models also have limitations in predicting drug toxicity due to interspecies differences. Furthermore, primary human hepatocytes (PHHs) are the gold standard for in vitro liver models. However, their use is limited due to limited accessibility to human liver tissue and functional instability. Furthermore, liver cancer cells, unlike normal cells, lack full expression or reduced function of drug-metabolizing enzymes, making them unsuitable for drug toxicity assessment. Therefore, it is necessary to develop a liver model that can mimic human liver metabolism while retaining drug-metabolizing capacity.
[0003] Organoids are organ-specific cell aggregates created by culturing, aggregating, or recombining stem cells in three dimensions. They are capable of self-renewal and are also called "mini-organs" or "organoids." Organoids are highly useful for basic research, as they resemble actual organs and allow for in vitro studies that are difficult to implement in animal models, such as molecular signaling regulation. Organoids are also a technology that can be very useful in various fields, such as human development, establishing disease models, evaluating drug efficacy, developing drug toxicity assessment platforms, and developing cell therapy agents.
[0004] Liver organoids are produced by extracting and culturing adult stem cells from liver tissue or by differentiating pluripotent stem cells, such as human induced pluripotent stem cells or embryonic stem cells, into hepatocytes and then culturing them. Because Matrigel cannot replicate the complex, in vivo liver tissue-specific microenvironment, improvements in liver organoid differentiation efficiency and function are needed. Therefore, there is a pressing need to develop a culture system capable of producing more mature and functional liver organoids.
[0005] The present inventors, during liver organoid research, confirmed the composition and ratio of a culture medium capable of producing organoids with a high degree of consistency with the patient's original tissue, and completed the present invention.
[0006] The present invention aims to provide a composition of a culture composition for efficient formation of liver organoids and a mixing ratio of the composition.
[0007] The present invention has been devised to solve the problems of conventional organoid culture techniques that use initial culture medium and growth (expansion) culture medium separately, and to provide a culture composition that can culture organoids with a single culture composition and can improve the genetic matching rate with the original tissue of a liver cancer patient during organoid production.
[0008] The present invention provides a composition for forming normal liver organoids or liver cancer organoids, comprising an R-spondin 3 (RSpo3) conditioned medium composition, neuregulin-1 (Nrg1), basic fibroblast growth factor (FGFb), insulin-like growth factor-1 (IGF-1), and CHIR99021 as active ingredients.
[0009] The composition of the present invention may further comprise N-acetyl-L-cysteine and forskolin.
[0010] The present invention also provides a medium for forming normal liver organoids or liver cancer organoids comprising the composition for forming normal liver organoids or liver cancer organoids.
[0011] The present invention also provides a method for forming a liver organoid (normal liver organoid or liver cancer organoid), which may include the steps of: a) isolating liver tissue (e.g., normal liver tissue or liver cancer tissue) from a subject (e.g., a non-liver cancer patient or a liver cancer patient) and then dissolving the same to obtain liver cells (e.g., normal liver cells or liver cancer cells); and b) adding the liver cells obtained in step a) to the composition of claim 1, culturing the liver cells, and growing them into liver organoids.
[0012] The composition for forming liver cancer organoids of the present invention may contain the above-mentioned Neuregulin-1 (Nrg1) at a concentration of 30 to 70 ng / ml and the above-mentioned CHIR99021 at a concentration of 1.00 to 2.00 μg / ml in the entire composition.
[0013] The present invention also provides a liver organoid produced by the above method, an animal model into which the organoid is xenografted, and a method for analyzing the therapeutic efficacy of a drug comprising a step of administering a target drug (e.g., an anticancer drug) to the animal model.
[0014] The present invention also provides a drug screening method comprising a step of administering a drug (e.g., an anticancer drug) candidate substance to an organoid or animal model produced by the above method.
[0015] When using the composition of the present invention, there is an advantage in that the problem of conventional organoid culture media requiring separate initial culture media is solved, and organoids can be formed with a single composition.
[0016] Liver organoids produced according to the present invention have a higher level of expression of liver markers than liver organoids produced using conventional media, are more similar to normal livers, and exhibit the same level of toxicity sensitivity as normal livers.
[0017] In the case of liver cancer organoids cultured with the composition of the present invention, the genetic match rate with the patient's original tissue is improved, so that the accuracy of drug screening, etc. using the produced liver cancer organoids can be increased.
[0018] When culturing liver cancer organoids using the composition of the present invention, the cell survival rate is high, so formation of liver cancer organoids is effective.
[0019] The present invention also has the advantage of reducing manufacturing costs by using basic FGF, IGF-I+, and NRG1 when manufacturing a composition for forming liver cancer organoids, and in particular, it is possible to reduce the time and cost required to purchase and manufacture Wnt conditioned media and Noggin used in conventional liver cancer organoid culture media.
[0020] Figure 1 shows the results of comparing the tissue digestion process in an experiment conducted to rescue an organoid model according to one embodiment of the present invention. The upper part of Figure 1 shows organoids cultured with a composition prepared by adding 0.01 g of Collagenase D and 0.0005 g of DNase I per 5 ml of Advanced DMEM / F12 according to a conventional method, and the lower image shows the expression of organoids cultured by adding 0.01 g of Collagenase D per 5 ml of Advanced DMEM / F12 according to the present invention. Referring to the image of Figure 1, it can be confirmed that the cell damage rate is reduced, the cell viability rate is increased, and the organoid establishment rate is higher in the lower image.
[0021] Figure 2 is an image showing the step-by-step process of forming liver cancer organoids from liver cancer cells cultured with a composition manufactured according to one embodiment of the present invention.
[0022] Figure 3 is a microscope image of a liver organoid tissue cultured in a conventional known medium (right) and a normal liver organoid tissue produced according to the present invention (left).
[0023] Figure 4 is a comparison of the patient's original tissue (left) and the organoid formed according to the present invention (right) according to one embodiment of the present invention.
[0024] Figure 5 shows the results of the initial culture process for organoid formation of liver cancer cells using the composition of the present invention, confirmed by date. Referring to Figure 4, it can be confirmed that initial culture is possible when forming liver cancer organoids using the composition of the present invention.
[0025] Figure 6 shows the results of confirming the initial culture of organoid formation of normal liver tissue cultured with the composition of the present invention by day.
[0026] Figure 7 shows the results of comparing organoids formed by culturing normal liver tissue with a known medium (left) and a composition prepared according to the present invention (right) according to one embodiment of the present invention.
[0027] FIG. 8 is a result confirming that the organoid cells of normal liver tissue cells cultured in a composition manufactured according to one embodiment of the present invention are normal cells and not cancer cells.
[0028] Figure 9 is a graph comparing cell survival rates over time after culturing cells in a complete medium composed of a composition (YHO-1 to YHO-08) manufactured according to the present invention and a composition of the present invention in which CHIR99021 is excluded.
[0029] Figure 10 is an image showing the cell viability after culturing cells in a complete medium (top) made of a composition (YHO-1 to YHO-08) manufactured according to the present invention and a composition of the present invention excluding CHIR99021 (bottom).
[0030] Figure 11 is a Venn diagram showing the results of analyzing the consistency between organoids produced according to one embodiment of the present invention and the patient tissue that served as the source for organoid production. The upper part of Figure 11 shows the consistency between organoids (YHO-3_Yonsei) cultured with the composition of the present invention and patient tissue, and the lower part shows the consistency between organoids (YHO-3_M) cultured with a medium produced according to a known protocol. In Figure 10, red represents the proportion of genetic material present only in the patient tissue (YHO-3_tissue_220722), green represents the proportion of genetic material present only in the produced organoid, and orange represents the proportion of the same genetic variation between the patient tissue and the produced organoid.
[0031] Figure 12 is an image confirming the formation of organoids cultured with a composition manufactured according to one embodiment of the present invention. Referring to Figure 12, it can be confirmed that organoids cultured with a composition according to the present invention exhibit a success rate of 77% or higher (based on cancer tissue examination).
[0032] Figures 13 and 14 illustrate the results of analyzing the mutation profiles of organoids cultured using a composition prepared according to the present invention and cancer tissue from a patient. Referring to Figures 13 and 14, the genetic identity between organoids cultured using a composition prepared according to the present invention and cancer tissue from a patient is greater than 80%.
[0033] Figure 15 shows the results of analyzing the expression level of liver markers in normal liver organoids produced according to the present invention.
[0034] Figure 16 shows the results of observing normal liver tissue (upper image) and normal liver organoid tissue (lower image) produced according to the present invention using the PAS staining method.
[0035] Figures 17 and 18 show the results of analyzing the degree of oxidative stress in normal liver organoids produced according to the present invention through CellROX staining.
[0036] Figure 19 shows the results of analyzing the sensitivity to stress of normal liver organoids produced according to the present invention based on the degree of albumin formation.
[0037] Hereinafter, the present invention will be described in detail. The advantages and features of the present invention, as well as the embodiments that achieve them, will be apparent with reference to the embodiments described below. However, the present invention is not limited to the embodiments disclosed below and may be implemented in various different forms. These embodiments are provided solely to ensure the complete disclosure of the present invention and to fully inform those skilled in the art of the scope of the invention. The present invention is defined solely by the scope of the claims. Like reference numerals designate like elements throughout the specification.
[0038] Unless otherwise defined, all terms (including technical and scientific terms) used herein may be used in a sense commonly understood by those of ordinary skill in the art to which the present invention pertains. Furthermore, terms defined in commonly used dictionaries are not to be interpreted ideally or excessively unless explicitly and specifically defined otherwise. The terminology used herein is for the purpose of describing embodiments and is not intended to limit the present invention. In this specification, singular forms also include plural forms, unless specifically stated otherwise.
[0039] Throughout the specification of the present invention, when a part is said to "include" a certain component, unless specifically stated otherwise, this does not exclude other components, but rather means that other components may be included. The terms "about," "substantially," and the like, as used throughout the specification of the present invention, are used in a meaning at or near the numerical value when manufacturing and material tolerances inherent to the meaning stated are presented, and are used to prevent unscrupulous infringers from unfairly exploiting disclosures that state precise or absolute values to aid understanding of the present invention.
[0040] Throughout the specification of the present invention, the term "combination thereof" included in the expressions in the Makushi format means one or more mixtures or combinations selected from the group consisting of the components described in the expressions in the Makushi format, and means including one or more selected from the group consisting of the components.
[0041] The present invention provides a composition for forming liver cancer organoids, comprising an R-spondin 3 (RSpo3) conditioned medium composition, neuregulin-1 (Nrg1), basic fibroblast growth factor (FGFb), insulin-like growth factor-1 (IGF-1), and CHIR99021 as active ingredients, for producing organoids with improved genetic matching with cancer tissue of a patient.
[0042] As used herein, "organoid" refers to a mini-organ created by culturing or recombining cells isolated from stem cells or organ cells. In the present invention, patient-derived liver cancer organoids are produced by cellularizing tissue isolated from a liver cancer patient and then culturing it using a composition according to the present invention. The liver cancer organoids according to the present invention are three-dimensionally cultured portions of cancer tissues collected from a liver cancer patient, and the constructed patient-derived liver cancer organoid line can be stored or continuously cultured for mass production.
[0043] The composition for forming liver cancer organoids of the present invention comprises, based on 300 ml of the total composition, 250 to 300 ml (preferably 250 to 260 ml) of (Advanced) DMEM / F12 (Dulbecco's Modified Eagle's Medium / F12), 1 to 5 ml (preferably 2 to 4 ml) of 1% L-alanyl-L-glutamine dipeptide (L-alanyl-L-glutamine dipeptide; product name: GlutaMax), 1 to 5 ml (preferably 2 to 4 ml) of 10 mM 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid (HEPES), 5 to 10 ml (preferably 5 to 7 ml) of vitamin A (1:50 B27 supplement w / o vitamin A), and 10% 20 to 50 ml of R-spondin 3 (RSpo3) conditioned medium composition, 0.5 mM N-Acetyl-L-Cysteine (NAC) 70 to 90 μg / ml (preferably 80 to 90 μg / ml), 10 mM nicotinamide 1 to 3 mg / ml, 10 nM [Leu15]-gastrin 10 to 30 ng / ml, 5 μM forskolin 1 to 3 μg / ml, 5 μM A83-01 1 to 3 μg / ml, NRG1 about 40 to 60 ng / ml (preferably 50 ng / ml), basic FGF about 50 to It may include, but is not limited to, 150 ng / ml (preferably 100 ng / ml), IGF-I at about 50 to 150 ng / ml (preferably 100 ng / ml), or CHIR99021 at about 1 to 5 μM (preferably 3 μM).
[0044] The composition of the present invention differs in composition from conventionally known culture media (see Table 1 below). The composition of the present invention utilizes basic FGF instead of FGF10, thereby reducing manufacturing costs by half without affecting cell proliferation.
[0045] In addition, the composition of the present invention uses RSPO3 instead of RSPO1, and it can be confirmed with the naked eye that contamination of normal liver cells is reduced and only cancer cells grow compared to when RSPO1 conditioned media is used, and it can be confirmed that the activity of RSPO is constantly maintained, thereby improving the proliferation of cancer cells.
[0046] The composition of the present invention can prevent the growth of cancer cells by preventing overgrowth of normal liver without adding an N2 supplement.
[0047] The composition of the present invention can also reduce costs (by more than half) by using 100 ng / ml IGF-I and 50 ng / ml NRG1 instead of EGF and HGF, and can prevent growth inhibition of cancer cells by HGF.
[0048] The composition of the present invention can also suppress the growth of normal liver cells in a liver cancer organoid growth environment by reducing the concentration of N-acetyl-L-cysteine to about 0.5 mM, and reduce contamination of normal liver cells, thereby inducing the growth of only cancer cells.
[0049] Comparison of the composition of the present invention with a previously known culture medium Conventional culture mediumComposition of the present invention (culture medium)Advanced DMEM / F12Advanced DMEM / F121% L-alanyl-L-glutamine dipeptide1% L-alanyl-L-glutamine dipeptide (product name: GlutaMax)10mM HEPES10mM HEPES1:50 B27 supplement w / o vitamin A1:50 B27 supplement w / o vitamin A1:100 N2 supplementx10% RSpo1 conditioned medium10% RSpo3 conditioned medium1.25mM N-acetyl-L-cysteine0.5mM N-acetyl-L-cysteine10mM Nicotinamide10mM Nicotinamide10nM [Leu15]-gastrin10nM [Leu15]-gastrin10μM forskolin5μM forskolin5μM A83-015μM A83-0150ng / ml EGF50ng / ml NRG1100ng / ml FGF10100ng / ml FGF basic25ng / ml HGF100ng / ml IGF-I-3μM CHIR9902110μM Y-2763210μM Y-27632
[0050] According to a preferred embodiment of the present invention, the NRG1 and basic FGF may be mixed in a weight ratio of 1:2 in the entire composition, and the NRG1 may be mixed with IGF-I in a weight ratio of 1:1, but is not limited thereto.
[0051] In addition, the medium included in the composition of the present invention may be selected from the group consisting of DMEM (Dulbeco's Modified Eagle's Medium), IMDM (Iscove's Modified Dulbecco's Medium), a-MEM (Alpha Modification of Eagle's Medium), F12 (Nutrient Mixture F-12), RPMI 1640, Williams's medium E, McCoy's 5A, and DMEM / F12 (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12), and preferably, (advanced) DMEM / F12 medium may be used, but is not limited thereto.
[0052] In the present invention, "FGF" or "fibroblast growth factor" is a family of nine structurally related polypeptides that are potent regulators of cell proliferation, differentiation, and general growth. "Basic Fibroblast Growth Factor (bFGF)" of the present invention, also known as FGF-2, is a heparin-binding growth factor that promotes the growth of cells of mesenchymal, neuroectodermal, and endothelial origin. "Basic Fibroblast Growth Factor" induces various types of cell proliferation in vitro, and promotes the growth of many other cells, including fibroblasts, myoblasts, osteoblasts, neuronal cells, endothelial cells, keratinocytes, and chondrocytes.
[0053] The neuregulin of the present invention is a glycoprotein belonging to the epithelial growth factor (EGF) family, and neuregulin-1 (Nrg1) is used in the present invention. Previously known techniques had the inconvenience of having to separately create two culture media under different conditions for the initial culture medium and the medium for growing cells when culturing liver cancer organoids, but the present invention reduces the inconvenience and cuts down on costs by enabling both initial culture and formation and maintenance of organoids with one composition (culture medium) using NRG1 and other components.
[0054] In the composition according to the present invention, the glutamine substitute is L-alanyl-L-glutamine dipeptide (product name: GlutaMax), and the TGF-β signaling inhibitor is 3-(6-methylpyridin-2-yl)-N-phenyl-4-(quinolin-4-yl)-1H-pyrazole-1-carbothioamide [3-(6-methylpyridin2-yl)-N-phenyl-4-(quinolin-4-yl)-1H-pyrazole-1-carbothioamide; A83-01], but is not limited thereto.
[0055] In the present invention, CHIR99021 refers to 6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile (CAS No. 252917-06-9).
[0056] The present invention also provides an anticancer agent screening method comprising a step of administering an anticancer agent candidate to a liver cancer organoid of the present invention or an animal model into which the liver cancer organoid has been xenografted.
[0057] The term "screening" as used herein means selecting a substance having a specific desired property from a candidate group consisting of various substances through a specific manipulation or evaluation method. The screening method provided in the present invention may first include a step of treating an anticancer agent candidate to a patient-derived liver cancer organoid provided in the present invention or an animal model into which the organoid has been xenografted. The anticancer agent candidate may be any one selected from the group consisting of natural compounds, synthetic compounds, RNA, DNA, polypeptides, enzymes, proteins, ligands, antibodies, antigens, metabolites of bacteria or fungi, and bioactive molecules, but is not limited thereto. When treating the anticancer agent candidate to the animal model in the present invention, the anticancer agent candidate may be administered orally, intravenously, intramuscularly, intraarterially, intramedullaryly, intrathecally, intracardiacly, transdermally, subcutaneously, intraperitoneally, intranasally, enterally, topically, sublingually, or rectally, but may be administered by an appropriate method selected depending on the type of animal model.
[0058] In the present invention, the efficacy of an anticancer candidate substance can be evaluated by performing a step of confirming a change in the expression level of a liver cancer-related biomarker in a patient-derived liver cancer organoid treated with the candidate substance or an animal model into which the organoid is xenografted, or observing a change in the proliferation, growth, invasiveness, or metastasis of cancer cells, or measuring it using a tool such as calipers. For example, if the expression level of a biomarker whose expression level is decreased or increased in liver cancer tissue is increased or decreased by the candidate substance, or the proliferation, growth, invasiveness, or metastasis of cancer cells is decreased, the candidate substance can be determined to have efficacy as an anticancer agent. Alternatively, if the candidate substance prevents or treats the onset of cancer, or improves the prognosis compared to a control substance, the candidate substance can be determined to have efficacy as an anticancer agent.
[0059]
[0060] Hereinafter, to aid understanding of the present invention, examples will be given in detail. However, the following examples are intended only to illustrate the scope of the present invention and are not intended to limit its scope. These examples are provided to more fully explain the present invention to those of average skill in the art.
[0061]
[0062] [Example 1]
[0063] 1-1. Preparation of the composition of the present invention
[0064] To prepare the composition of the present invention, the composition was prepared in the ratio shown in Table 2 below. The composition prepared according to Example 1 is used in the following examples.
[0065] Composition of the present invention composition (or culture medium) Ingredient concentration (based on 300ml of total composition) Advanced DMEM / F1228ml1% glutamax3ml10mM HEPES3ml1:50 B27 supplement w / o vitamin A6ml10% RSpo3 conditioned medium30ml (10%)0.5mM N-acetyl-L-cysteine81.60μg / ml10mM Nicotinamide 1.22mg / ml10nM [Leu15]-gastrin20.98ng / ml5μM forskolin2.05μg / ml5μM A83-012.11μg / mlNRG150ng / mlFGF basic100ng / mlIGF-I100ng / ml3μM CHIR990211.40 μg / ml10μM Y-276323.33μg / ml
[0066]
[0067] 1-2. Preparation of the culture medium (control group)
[0068] Each culture solution prepared according to Tables 3 and 4 below was used to form a control group.
[0069] Known culture medium (control) - initial cell establishment mediumIngredient concentration (based on 300ml of total composition) Advanced DMEM / F12163ml1% glutamax3ml10mM HEPES3ml1:50 B27 supplement w / o vitamin A6ml1:100 N2supplement3ml30% Wnt3a conditioned medium90ml10% RSpo1 conditioned medium30ml1.25mM N-acetyl-L-cysteine204μg / ml10mM Nicotinamide1.22mg / mlNoggin25ng / ml10nM [Leu15]-gastrin20.98ng / ml10μM forskolin4.1μg / ml5μM A83-012.11μg / mlEGF50ng / mlFGF10100ng / mlHGF25ng / ml10μM Y-276323.33μg / ml
[0070]
[0071] Composition of known culture medium (control) - subculture medium Ingredient concentration (based on 300ml of total composition) Advanced DMEM / F1228ml1% glutamax3ml10mM HEPES3ml1:50 B27 supplement w / o vitamin A6ml1:100 N2supplement3ml10% Rspo1 conditioned medium30ml1.25mM N-acetyl-L-cysteine204μg / ml10mM Nicotinamide1.22mg / ml10nM [Leu15]-gastrin20.98ng / ml10μM forskolin4.1μg / ml5μM A83-012.11μg / mlEGF50ng / mlFGF10100ng / mlHGF25ng / ml10μM Y-276323.33μg / ml
[0072]
[0073] [Example 2]
[0074] Production of normal liver organoids and liver cancer organoids
[0075] 2-1. Production of normal liver organoids
[0076] Liver tissue (normal liver tissue) was obtained from a subject (human) with or without suspected liver cancer. The normal liver tissue was washed in a cold (4 to 10°C) culture medium, preferably Advanced-DMEM / F12 (Gibco), and then the tissue was cut into approximately 2-3 mm pieces and further washed with cold dissociation buffer (collagenase in DMEM medium). The tissue pieces were incubated in a shaker with the dissociation buffer, preferably at about 37°C, for about 1-2 hours. The tissue pieces were then suspended in 10 ml of cold (4 to 10°C) isolation buffer and passed through a 70 μm strainer. The cells and supernatant were then separated using a centrifuge (1800 rpm, 3 minutes), the supernatant containing dead cells was discarded, and the supernatant was washed with 5 ml of red blood cell lysis solution. Next, centrifugation was performed to obtain a suspension containing normal liver cells. The isolated liver cells were seeded onto 50 μl of Matrigel, preferably at a ratio of approximately 2,000 cells / well.
[0077] The seeded normal liver cells were cultured in a culture medium prepared according to Example 1-1 above at 37°C and 5% CO2 conditions.
[0078] It was confirmed that the normal liver organoid tissue (left side of Fig. 3) produced according to this example was produced at the same level as the normal liver organoid (left side of Fig. 3) produced using the conventional initial medium according to the following Example 2-3 (microscopic observation (OLYMPUS DP74)).
[0079]
[0080] 2-2. Production of liver cancer organoids
[0081] Liver cancer tissues derived from liver cancer patients were washed in a low-temperature (4-10°C) culture medium, preferably Advanced-DMEM / F12 (Gibco), and then cut into approximately 2-3 mm pieces, which were further washed with a low-temperature dissociation buffer (collagenase in DMEM medium). The tissue fragments were incubated with the dissociation buffer on a shaker, preferably at about 37°C, for about 1-2 hours. The tissue fragments were then suspended in 10 ml of low-temperature (4-10°C) isolation buffer and passed through a 70 μm strainer. The cells and supernatant were then separated using a centrifuge (1800 rpm, 3 minutes), the supernatant containing dead cells was discarded, and the precipitate was washed with 5 ml of red blood cell lysis solution. The centrifugation was then performed, and a suspension containing patient-derived liver cancer cells was obtained. Isolated liver cancer cells were seeded in 50 μl of Matrigel, preferably at an approximate ratio of 2,000 cells / well.
[0082] The seeded normal liver cells were cultured in a culture medium prepared according to Example 1-1 above at 37°C and 5% CO2 conditions.
[0083] The process for forming a liver cancer organoid manufactured according to the present invention is as illustrated in Fig. 2 below. When the liver cancer organoid finally manufactured according to Fig. 2 (right image of Fig. 4) is compared with the original tissue of the patient (left image of Fig. 4), it can be confirmed that the liver cancer organoid manufactured according to the present invention is formed into a tissue of the same level as the original tissue of the patient.
[0084]
[0085] 2-3. Production of control organoids
[0086] After obtaining liver cells and liver cancer cells according to the methods of Examples 2-1 and 2-2, each was cultured in an initial cell establishment medium and a subculture medium prepared according to the method of Example 1-2 at 37°C and 5% CO2 conditions.
[0087]
[0088] [Example 3]
[0089] Confirmation of the feasibility of initial liver organoid culture using a composition according to the present invention
[0090] In conventional studies, two separate media are required for initial culture and growth (expansion) when producing normal liver organoids or liver cancer organoids. However, the composition for forming liver organoids manufactured according to the present invention enables both initial culture and cell growth (expansion) with a single medium. That is, when the composition of the present invention is used, both initial culture and growth (expansion) of organoids using normal liver tissue, and initial culture and growth (expansion) of organoids using liver cancer tissue are possible.
[0091] Referring to FIG. 5, it can be confirmed that the initial culture of the organoid formed based on liver cancer cells was successful, and referring to FIGS. 6 and 7, it can be confirmed that the initial culture was successful when forming normal liver organoids based on liver cancer cells using the composition of the present invention.
[0092] Specifically, Fig. 7 shows the results of forming normal liver tissue organoids using normal liver cells. The left side of Fig. 7 shows the results of culturing with the initial culture medium of the conventional (control) according to Example 2-3, and the right side shows the results of culturing with the composition of the present invention according to Example 2-1. As shown in the image of Fig. 7, it can be confirmed that the normal liver organoids of the present invention can be initially cultured with the same level as normal liver tissue organoids prepared with the initial culture medium of the conventional. It can be confirmed that the normal organoids cultured with the composition of the present invention were well formed into normal liver organoids as a result of karyotype analysis (see Fig. 7).
[0093]
[0094] [Example 4]
[0095] Confirmation of liver cancer organoid formation according to the presence or absence of CHIR99021, a composition of the present invention
[0096] In the composition according to the present invention, CHIR99021 is an essential component. Accordingly, in this example, cell viability was analyzed depending on the presence / absence of CHIR99021 in the composition.
[0097] When liver cancer organoids were grown using the complete composition (complete medium) prepared according to the present invention using the established organoids, and when liver cancer organoids were grown using the composition excluding CHIR99021 from the complete composition, the culture medium was divided and cultured for 3 months to eliminate any residual effects. Subsequently, organoids of the complete composition and the composition excluding CHIR99021 were continuously subcultured to confirm the cell growth rate and the point at which the cells no longer differentiated, and then compared.
[0098] Referring to FIG. 9, in the case of the complete composition (complete medium, including CHIR99021) manufactured according to the present invention, it can be confirmed that cells are growing in all compositions, but in the case of the composition from which CHIR99021 is removed (-CHIR in FIG. 9), it can be confirmed that the cell survival rate decreases with each week. In particular, referring to FIG. 10, when the same number of cells (5000 cells) were seeded per well, it can be confirmed that cell growth is prominent in the complete medium (composition manufactured according to the present invention) including CHIR99021 on the 12th day.
[0099] That is, it can be seen that the composition of the present invention includes CHIR99021, thereby improving cell survival rate.
[0100]
[0101] [Example 5]
[0102] Confirmation of formation of liver cancer organoids
[0103] 5-1. Confirmation of genetic match with the patient's liver cancer tissue
[0104] To determine whether the liver cancer organoids manufactured according to the present invention have a certain degree of genetic similarity with the patient's original tissue, genetic analysis was performed.
[0105] DNA was extracted from liver cancer organoids cultured using the above method and subjected to whole-exome sequencing. This method analyzes abnormalities in exonic regions, CNVs, and gene structural mutations, focusing on exons or protein-coding regions of the genome. Through this analysis, mutation patterns and the expression levels of cancer-causing genes were compared between the primary liver cancer tissue and the tissue-derived organoids.
[0106] Using the individual VCF (Variant Call Format) results, we analyzed how identical the genetic mutations were between the patient's original tissue and the organoids grown from each culture medium using the patient tissue corresponding to YHO-3 through WES (whole exome sequencing), and presented this in a Venn diagram (see Figure 11).
[0107] In Fig. 11, the genetic identity of YHO-3_Yonsei (liver cancer organoid cultured with a composition according to the present invention) with the original tissue was 88.93%, which was higher than the identity of 61.87% with the original tissue of YHO-3_M (liver cancer organoid cultured with a tissue digestion protocol and a conventional culture medium published in a previous paper (Nat Med. 2017 Dec; 23(12): 1424-1435, Cell Rep. 2018 Jul 31; 24(5): 1363-1376.)).
[0108] In addition, as shown in Fig. 12, the success rate in the existing paper was about 26% based on biopsy tumor tissue, but the success rate was about 77% based on biopsy tumor tissue (10 organoids were established from 13 patient tissues), confirming that organoid production is easier.
[0109] Finally, the analysis of the cancer-related mutation profile of the liver cancer organoid and biopsy tumor tissue manufactured according to the invention showed a match rate of 80% or more (see Figures 13 and 14), indicating that when the composition of the present invention is used, an organoid having a high match rate with the patient's original tissue can be formed.
[0110]
[0111] [Example 6]
[0112] Confirmation of formation of normal liver organoids
[0113] 6-1. Confirmation of heptic marker expression
[0114] Normal liver organoids produced according to the present invention were each fixed with 4% paraformaldehyde, seeded on Histogel, solidified, and then fixed in 10% NB formalin. After that, paraffin blocks were produced, sectioned at 4 μm thickness, and adhered to slide glasses. Then, antibodies against normal liver tissue characteristic expression markers (HepPar1, CK18, MRP2, E-cadherin, HNF4 alpha, Albumin) were attached to confirm fluorescence expression. The fluorescently stained slides were observed using a super-resolution confocal microscope (Confocal microscope LSM 780, ZEISS). Normal liver organoids produced according to the present invention were obtained, and cDNA was produced using the RNeasy Mini kit, a kit for extracting RNA, and a cDNA synthesis kit for synthesizing DNA complementary to the RNA. The expression levels of hepatocyte- and cholangiocyte-specific genes in normal liver organoids were relatively analyzed and compared using equipment (CFX96, Bio-rad) that quantitatively displays the results of polymerase chain reaction (PCR) using synthesized cDNA and SYBR in real time.
[0115] Referring to Figure 15, it can be confirmed that hepatocyte markers and cholangiocyte markers are expressed at levels similar to or higher than those in organoids cultured according to a conventional culture medium (Example 2-3) (indicated as basic in Figure 15).
[0116]
[0117] 6-2. Histological / Functional Analysis - PAS Staining
[0118] Normal liver tissue and normal liver organoids produced according to the present invention were each fixed with 4% paraformaldehyde, seeded on Histogel, solidified, and then fixed in 10% NB formalin. Afterwards, paraffin blocks were produced, sectioned at 4 μm thickness using a microtome, and adhered to slide glass using a microtome, followed by staining using the Alcian Blue PAS Stain Kit. The slides were observed through an optical microscope (BX43, Olympus, Japan).
[0119] Referring to FIG. 16, it can be confirmed that normal liver organoids produced according to the present invention exhibit carbohydrates at similar levels as normal liver tissue (upper image of FIG. 16). In other words, it can be confirmed that normal liver organoids produced according to the present invention possess the glycogen storage and function of mature hepatocytes.
[0120]
[0121] 6-3. Analysis of reactive oxygen species (ROS) production - CellRox staining
[0122] Normal liver organoid tissues produced according to the present invention were placed in 12-well culture plates at 2X10 5 After dividing by cell / well condition and stabilizing for 96 hours, acetaminophen (0 mM, 1 mM, 5 mM, 10 mM) was treated and cultured for 24 hours. Each cell was stained with CellRox Deep Red Reagent (Thermo Fisher, C10422) and observed under a fluorescence microscope (Fig. 17). After that, the number of Deep Red-stained dots per organoid was counted to quantitatively analyze the degree of stress of hepatocytes against reactive oxygen species (Fig. 18).
[0123] Referring to FIGS. 17 and 18, it can be confirmed that the normal liver organoids produced according to the present invention show an increase in reactive oxygen species in response to an increase in oxidative stress (acetaminophen). In other words, it can be confirmed that the oxidative stress experienced by normal liver tissue can be measured using the normal liver organoids produced according to the present invention.
[0124]
[0125] 6-4. Checking sensitivity to toxicity
[0126] In this example, we aimed to determine whether the produced normal liver organoids were affected by toxicity in the same way as normal liver tissue.
[0127] Normal liver organoid tissues produced according to the present invention were placed in 12-well culture plates at 2X10 5 After dividing into cells / well conditions and stabilizing for 96 hours, the cells were treated with acetaminophen (0 mM, 1 mM, 5 mM, 10 mM) and cultured for 24 hours, and then albumin expressed in normal liver organoids was quantitatively analyzed.
[0128] Referring to FIG. 19, it can be confirmed that the normal organoids produced according to the present invention have a decreased expression level of albumin as the amount of acetaminophen treated increases (as liver toxicity increases).
[0129] That is, it can be confirmed that the normal liver organoid produced according to the present invention exhibits the same level of sensitivity to toxicity as a normal liver, and thus screening of drugs applicable to a normal liver is possible.
[0130]
[0131] The present invention has been described above, focusing on preferred embodiments thereof. Those skilled in the art will appreciate that the present invention can be implemented in modified forms without departing from its essential characteristics. Therefore, the disclosed embodiments should be considered illustrative rather than limiting. The scope of the present invention is set forth in the claims, not the foregoing description, and all differences within the scope equivalent thereto should be construed as being encompassed by the present invention.
Claims
1. A composition for forming liver organoids, comprising R-spondin 3 (RSpo3) conditioned medium composition, neuregulin-1 (Nrg1), basic fibroblast growth factor (FGFb), insulin-like growth factor-1 (IGF-1), and CHIR99021 as active ingredients.
2. In paragraph 1, A composition for forming liver organoids, wherein the liver organoids are normal liver or liver cancer organoids.
3. In paragraph 1, A composition for forming liver organoids, wherein the composition further comprises N-acetyl-L-cysteine and forskolin.
4. In paragraph 1, A composition for forming liver organoids, wherein the above-mentioned neuregulin-1 (Neuregulin-1; Nrg1) is included in the entire composition at a concentration of 30 to 70 ng / ml.
5. In paragraph 1, A composition for forming liver organoids, wherein the CHIR99021 is included in the entire composition at a concentration of 1.00 to 2.00 μg / ml.
6. A medium for forming liver organoids, comprising a composition according to any one of claims 1 to 5.
7. In the method for forming liver organoids, a) A step of isolating liver tissue from a subject and then dissolving it to obtain liver cells; b) A method for forming a liver organoid, comprising the step of adding the liver cells obtained in step a) to the composition of the first clause, culturing the liver cells, and growing them into liver organoids.
8. In paragraph 7, The above liver organoids include normal liver or liver cancer organoids, In step a) of normal liver organoid formation, the liver cells obtained from the subject are normal liver cells, A method for forming a liver organoid, wherein the liver cells obtained from the subject in step a) are liver cancer cells.
9. In paragraph 7, A method for forming a liver organoid, wherein the composition of step b) comprises neuregulin-1 (Nrg1) at a concentration of 30 to 70 ng / ml in the entire composition.
10. In paragraph 7, A method for forming a liver organoid, wherein the composition of step b) comprises CHIR99021 at a concentration of 1.00 to 2.00 μg / ml in the entire composition.
11. Liver organoids manufactured by the method of Article 7.
12. Animal model in which the liver organoid of Article 11 has been xenotransplanted.
13. A method for analyzing the therapeutic efficacy of a drug, comprising administering a drug to a liver organoid of claim 11 or an animal model of claim 12.
14. In paragraph 13, The above drug is an anticancer drug, and a method for analyzing the therapeutic efficacy of the drug.
15. A drug screening method comprising a step of administering a drug candidate to the liver organoid of claim 11 or the animal model of claim 12.
16. In paragraph 15, A drug screening method wherein the above drug is an anticancer agent.
Citation Information
Patent Citations
Massage Chair
KR1020220136579A
Apparatus for planning cutting path of surgical robot, and mehtod thereof
KR1020240041681A
Toothbrush capable of supplying self toothpaste
KR102132182B1
KR20200140064A
KR20220139577A
